Vitrolife: Industrious and purposeful consolidation - Redeye

Vitrolife’s CEO Bronwyn Brophy came across as executive and resourceful during her first CMD at Vitrolife. The new 5-year target is >10% organic growth target is perhaps the most interesting. Our take is that Vitrolife has established a sufficient footprint where future opportunities are more related to regional commercial opportunities, innovation combined with complementary acquisitions supporting the vertical integration strategy. Our updated view is a base case valuation of SEK 235 (220) and a Bull Case of SEK 375 (330), and a Bear Case of SEK 95 (95).

Länk till analysen i sin helhet: https://www.redeye.se/research/967283/vitrolife-industrious-and-purposeful-consolidation?utm_source=finwire&utm_medium=RSS